Detection of aberrant androgen receptor transcripts in circulating tumour cells as a predictor of resistance to AR- directed treatment in patients with castration-resistant prostate cancer.

Detection of aberrant androgen receptor transcripts in circulating tumour cells as a predictor of resistance to AR- directed treatment in patients with castration-resistant prostate cancer. - Detection of AR splice variants in CTC of men with CRPC.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42793

Enrollment

Registered

2015-08-06

Start date

2015-05-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

castration-resistent prostate cancer progression during hormonal treatment

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Willing and able to provide written informed consent 2. Male and age >= 18 years 3. Histologically or cytologically confirmed adenocarcinoma of the prostate 4. Patients eligible to receive enzalutamide or abiraterone acetate as judged by the treating physician 5. Patients with or without prior chemotherapy regimens

Exclusion criteria

Exclusion criteria: 1. Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection. 2. Not willing to comply with the procedural requirements (extra blood draw) of this protocol. 3. Any criteria which renders patients ineligible for new AR-directed therapy (i.e. abiraterone acetate, enzalutamide).

Design outcomes

Primary

Measure	Time frame
The determination of the clinical relevance for the presence or absence of androgen receptor splice variants in circulating tumour cells from patients with CRPC (with or without previous taxane chemotherapy) is the primary endpoint of this study.	—

Countries

Netherlands

Outcome results